Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 03, 2025 07:00 ET | Source: Iolyx Therapeutics, Inc.

Iolyx Therapeutics Enters Strategic Agreement with Laboratoires Théa to Develop and Commercialize ILYX-002 intended for the Treatment of Autoimmune Associated Dry Eye Disease and Secures Series B Funding for Retinal Pipeline

Deal with Laboratoires Théa representing a total value of up to $280 million including clinical, regulatory and commercial conditional milestones, commercial royalties, and development responsibility...
October 09, 2025 08:30 ET | Source: Iolyx Therapeutics, Inc.

Iolyx Therapeutics Announces Upcoming Presentation at Eyecelerator 2025 and Poster at the American Academy of Ophthalmology Annual Meeting

BURLINGAME, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Iolyx Therapeutics, a clinical-stage biotechnology company developing therapeutics at the intersection of ocular inflammation and autoimmunity,...
May 27, 2025 08:30 ET | Source: Iolyx Therapeutics, Inc.

Iolyx Therapeutics Announces Phase 2 Results for ILYX-002 in Autoimmune Dry Eye Disease

Results shared during a R&D Update featuring prominent experts in the field of ophthalmology A favorable safety profile plus significant ocular surface healing support advancement to Phase 3 ...
March 12, 2025 08:30 ET | Source: Iolyx Therapeutics, Inc.

Iolyx Therapeutics to Present at Multiple Upcoming Ophthalmology Conferences

BURLINGAME, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Iolyx Therapeutics, a clinical-stage biotechnology company focused on the development of therapeutics at the intersection of ocular...